These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 17210246)
1. Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways. Kaul A; Overmeyer JH; Maltese WA Cell Signal; 2007 May; 19(5):1034-43. PubMed ID: 17210246 [TBL] [Abstract][Full Text] [Related]
2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
3. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase. Lee J; Choi KJ; Lim MJ; Hong F; Choi TG; Tak E; Lee S; Kim YJ; Chang SG; Cho JM; Ha J; Kim SS Cell Res; 2010 Aug; 20(8):919-34. PubMed ID: 20603646 [TBL] [Abstract][Full Text] [Related]
4. Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21. Rosário M; Paterson HF; Marshall CJ Mol Cell Biol; 2001 Jun; 21(11):3750-62. PubMed ID: 11340168 [TBL] [Abstract][Full Text] [Related]
5. Secreted Glioblastoma Nanovesicles Contain Intracellular Signaling Proteins and Active Ras Incorporated in a Farnesylation-dependent Manner. Luhtala N; Aslanian A; Yates JR; Hunter T J Biol Chem; 2017 Jan; 292(2):611-628. PubMed ID: 27909058 [TBL] [Abstract][Full Text] [Related]
6. A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth. Ehrhardt GR; Korherr C; Wieler JS; Knaus M; Schrader JW Oncogene; 2001 Jan; 20(2):188-97. PubMed ID: 11313946 [TBL] [Abstract][Full Text] [Related]
7. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
8. Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6. Bhanot H; Young AM; Overmeyer JH; Maltese WA Mol Cancer Res; 2010 Oct; 8(10):1358-74. PubMed ID: 20713492 [TBL] [Abstract][Full Text] [Related]
9. Depletion of K-Ras promotes proteasome degradation of survivin. Tecleab A; Sebti SM Cell Cycle; 2013 Feb; 12(3):522-32. PubMed ID: 23324341 [TBL] [Abstract][Full Text] [Related]
10. A role for RalGDS and a novel Ras effector in the Ras-mediated inhibition of skeletal myogenesis. Ramocki MB; White MA; Konieczny SF; Taparowsky EJ J Biol Chem; 1998 Jul; 273(28):17696-701. PubMed ID: 9651367 [TBL] [Abstract][Full Text] [Related]
11. Stimulation of gene induction and cell growth by the Ras effector Rlf. Wolthuis RM; de Ruiter ND; Cool RH; Bos JL EMBO J; 1997 Nov; 16(22):6748-61. PubMed ID: 9362489 [TBL] [Abstract][Full Text] [Related]
12. Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis. Overmeyer JH; Kaul A; Johnson EE; Maltese WA Mol Cancer Res; 2008 Jun; 6(6):965-77. PubMed ID: 18567800 [TBL] [Abstract][Full Text] [Related]
13. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. Genot E; Reif K; Beach S; Kramer I; Cantrell D Oncogene; 1998 Oct; 17(13):1731-8. PubMed ID: 9796702 [TBL] [Abstract][Full Text] [Related]
14. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581 [TBL] [Abstract][Full Text] [Related]
15. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399 [TBL] [Abstract][Full Text] [Related]
17. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353 [TBL] [Abstract][Full Text] [Related]
18. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018 [TBL] [Abstract][Full Text] [Related]
19. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. Choi JA; Park MT; Kang CM; Um HD; Bae S; Lee KH; Kim TH; Kim JH; Cho CK; Lee YS; Chung HY; Lee SJ Oncogene; 2004 Jan; 23(1):9-20. PubMed ID: 14712206 [TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding. Ting PY; Johnson CW; Fang C; Cao X; Graeber TG; Mattos C; Colicelli J FASEB J; 2015 Sep; 29(9):3750-61. PubMed ID: 25999467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]